Objective To study the effect of cisplatin of different concentrations on the ovarian function in C57BL/6 mice, and to explore the minimum effective concentration that can cause premature ovarian insufficiency (POI) in C57BL/6 mice, aiming to provide a safe, reliable, and convenient POI model for clinical research.

Methods Totally, 60 female C57BL/6 mice (6-8 weeks) of SPF grade were randomly divided into control group, dose 1.0 group (1 mg/kg), dose 1.5 group (1.5 mg/kg), and dose 2.0 group (2 mg/kg), different concentrations of cisplatin were administered by the traditional intraperitoneal route for 7 days in cisplatin group.

Results In 1.0 group, ovarian tissue morphology, follicle count, and serum hormone levels were slightly different from those in the control group, but without statistical significance, therefore could not be used for modeling. In 1.5 group, the ovaries of mice were damaged heavily, their weight dropped steadily, but the general state was good, the mortality rate was low, the recovery rate of estrous cycle was low, and the ovarian histomorphology, follicle count, and serum hormone levels had statistical significance changes compared with those in the control group, but the degree of change was relatively gentle, which was suitable for the establishment of POI model. In 2.0 group, the ovaries of mice were severely damaged, their body weight dropped dramatically, the general condition was poor, and there were persistent estrous intervals. The ovarian histomorphology, follicle count, and serum hormone levels were significantly different from those in the control group, but the changes were dramatic, which was not conducive to the experimental study.

Conclusions The suitable and effective concentration of cisplatin for establishing POI model in C57BL/6 mice is 1.5 mg/kg. The ovarian tissue damage of the model established by this drug regimen is relatively stable, which can well simulate the changes in hormone levels of POI patients, and the animal has a good tolerance, which is conducive to the development of treatment studies and more suitable for the evaluation of POI treatment regimen.